Neuphoria Therapeutics Inc. Common Stock (NEUP)

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

Neuphoria Therapeutics has completed target enrollment of 332 participants in its Phase 3 AFFIRM-1 trial for BNC-210, a potential treatment for social anxiety disorder, with initial Phase 3 data expected in early Q4 2025.